Tissue engineered fetal skin constructs for paediatric burns

Hohlfeld, Judith; Roessingh, Anthony de Buys; Hirt‐Burri, Nathalie; Chaubert, Pascal; Gerber, Stefan; Scaletta, Corinne; Hohlfeld, P.; Applegate, Lee Ann

doi:10.1016/s0140-6736(05)67107-3

Cited by 157 publications

(202 citation statements)

References 7 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…The study by Noorderbos et al [81], comparing Trancyte dressings with silver sulphadiazine cream, was criticised by Pape and Byrne [55] because no objective selection was used to show that the 'paired' burns were of similar depth. Norbury et al [82] suggested that Hohlfeld et al [83] should have used LDI to assess deep dermal wounds treated with fetal skin constructs. The study by Kumar et al [84] was the first to objectively confirm the depth of wounds selected for comparison of treatments: TranCyte, Biobrane, and silver sulphadiazine cream.…”

Section: Discussionmentioning

confidence: 99%

Assessment of burn depth and burn wound healing potential

Monstrey

Hoeksema

Verbelen

et al. 2008

Burns

370

266

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Assessment of burn depth and burn wound healing potential

Monstrey

Hoeksema

Verbelen

et al. 2008

Burns

370

266

View full text Add to dashboard Cite

“…They can be isolated from fetal tissues, which follow the embryonic stage of 9 weeks of development. Fetal cells are mature, fully differentiated cells and capable of proliferating rapidly [45,46] and have a higher resistance to oxydatif stress than adult cells [47]. Moreover, fetal tissue is not easily rejected by the recipient due to the low levels of histocompatibility antigens [43,48,49].…”

Section: Introductionmentioning

confidence: 99%

Human muscular fetal cells: a potential cell source for muscular therapies

Hirt‐Burri¹,

Roessingh²,

Scaletta

et al. 2007

Pediatr Surg Int

Self Cite

View full text Add to dashboard Cite

Myoblast transfer therapy has been extensively studied for a wide range of clinical applications, such as tissue engineering for muscular loss, cardiac surgery or Duchenne Muscular Dystrophy treatment. However, this approach has been hindered by numerous limitations, including early myoblast death after injection and specific immune response after transplantation with allogenic cells. Different cell sources have been analyzed to overcome some of these limitations. The object of our study was to investigate the growth potential, characterization and integration in vivo of human primary fetal skeletal muscle cells. These data together show the potential for the creation of a cell bank to be used as a cell source for muscle cell therapy and tissue engineering. For this purpose, we developed primary muscular cell cultures from biopsies of human male thigh muscle from a 16-week-old fetus and from donors of 13 and 30 years old. We show that fetal myogenic cells can be successfully isolated and expanded in vitro from human fetal muscle biopsies, and that fetal cells have higher growth capacities when compared to young and adult cells. We confirm lineage specificity by comparing fetal muscle cells to fetal skin and bone cells in vitro by immunohistochemistry with desmin and 5.1H11 antibodies. For the feasibility of the cell bank, we ensured that fetal muscle cells retained intrinsic characteristics after 5 years cryopreservation. Finally, human fetal muscle cells marked with PKH26 were injected in normal C57BL/6 mice and were found to be present up to 4 days. In conclusion we estimate that a human fetal skeletal muscle cell bank can be created for potential muscle cell therapy and tissue engineering.

show abstract

“…[5][6][7] The temporary covering can be prepared from off-theshelf frozen vials of fetal skin cells, and the burns heal within about 14 days.…”

Section: An Imperfect Matchmentioning

confidence: 99%